Global Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2024-2031

Report ID: 918314 | Published Date: Jan 2025 | No. of Page: 127 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 HER-2 Targeted Drugs
        1.2.3 CDK4/6 Inhibitors
        1.2.4 PARP Targeted Drugs
        1.2.5 PI3K/AKT/mTor Pathway Inhibitors
        1.2.6 ER Targeted Drugs
        1.2.7 Aromatase Inhibitors
        1.2.8 Tubulin Inhibitors
        1.2.9 VEGF Targeted Drugs
        1.2.10 YTMS Targeted Drugs
        1.2.11 Other
    1.3 Market by Application
        1.3.1 Global Targeted Drugs for Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Drug Center
        1.3.5 Other
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Targeted Drugs for Breast Cancer Market Perspective (2016-2027)
    2.2 Targeted Drugs for Breast Cancer Growth Trends by Regions
        2.2.1 Targeted Drugs for Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Targeted Drugs for Breast Cancer Historic Market Share by Regions (2016-2021)
        2.2.3 Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2022-2027)
    2.3 Targeted Drugs for Breast Cancer Industry Dynamic
        2.3.1 Targeted Drugs for Breast Cancer Market Trends
        2.3.2 Targeted Drugs for Breast Cancer Market Drivers
        2.3.3 Targeted Drugs for Breast Cancer Market Challenges
        2.3.4 Targeted Drugs for Breast Cancer Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue
        3.1.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue (2016-2021)
        3.1.2 Global Targeted Drugs for Breast Cancer Revenue Market Share by Players (2016-2021)
    3.2 Global Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Targeted Drugs for Breast Cancer Revenue
    3.4 Global Targeted Drugs for Breast Cancer Market Concentration Ratio
        3.4.1 Global Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Breast Cancer Revenue in 2020
    3.5 Targeted Drugs for Breast Cancer Key Players Head office and Area Served
    3.6 Key Players Targeted Drugs for Breast Cancer Product Solution and Service
    3.7 Date of Enter into Targeted Drugs for Breast Cancer Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drugs for Breast Cancer Breakdown Data by Type
    4.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Type (2016-2021)
    4.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2022-2027)

5 Targeted Drugs for Breast Cancer Breakdown Data by Application
    5.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Application (2016-2021)
    5.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Targeted Drugs for Breast Cancer Market Size (2016-2027)
    6.2 North America Targeted Drugs for Breast Cancer Market Size by Type
        6.2.1 North America Targeted Drugs for Breast Cancer Market Size by Type (2016-2021)
        6.2.2 North America Targeted Drugs for Breast Cancer Market Size by Type (2022-2027)
        6.2.3 North America Targeted Drugs for Breast Cancer Market Size by Type (2016-2027)
    6.3 North America Targeted Drugs for Breast Cancer Market Size by Application
        6.3.1 North America Targeted Drugs for Breast Cancer Market Size by Application (2016-2021)
        6.3.2 North America Targeted Drugs for Breast Cancer Market Size by Application (2022-2027)
        6.3.3 North America Targeted Drugs for Breast Cancer Market Size by Application (2016-2027)
    6.4 North America Targeted Drugs for Breast Cancer Market Size by Country
        6.4.1 North America Targeted Drugs for Breast Cancer Market Size by Country (2016-2021)
        6.4.2 North America Targeted Drugs for Breast Cancer Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Targeted Drugs for Breast Cancer Market Size (2016-2027)
    7.2 Europe Targeted Drugs for Breast Cancer Market Size by Type
        7.2.1 Europe Targeted Drugs for Breast Cancer Market Size by Type (2016-2021)
        7.2.2 Europe Targeted Drugs for Breast Cancer Market Size by Type (2022-2027)
        7.2.3 Europe Targeted Drugs for Breast Cancer Market Size by Type (2016-2027)
    7.3 Europe Targeted Drugs for Breast Cancer Market Size by Application
        7.3.1 Europe Targeted Drugs for Breast Cancer Market Size by Application (2016-2021)
        7.3.2 Europe Targeted Drugs for Breast Cancer Market Size by Application (2022-2027)
        7.3.3 Europe Targeted Drugs for Breast Cancer Market Size by Application (2016-2027)
    7.4 Europe Targeted Drugs for Breast Cancer Market Size by Country
        7.4.1 Europe Targeted Drugs for Breast Cancer Market Size by Country (2016-2021)
        7.4.2 Europe Targeted Drugs for Breast Cancer Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Targeted Drugs for Breast Cancer Market Size (2016-2027)
    8.2 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Type
        8.2.1 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Type (2016-2027)
    8.3 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Application
        8.3.1 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Application (2016-2027)
    8.4 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region
        8.4.1 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Targeted Drugs for Breast Cancer Market Size (2016-2027)
    9.2 Latin America Targeted Drugs for Breast Cancer Market Size by Type
        9.2.1 Latin America Targeted Drugs for Breast Cancer Market Size by Type (2016-2021)
        9.2.2 Latin America Targeted Drugs for Breast Cancer Market Size by Type (2022-2027)
        9.2.3 Latin America Targeted Drugs for Breast Cancer Market Size by Type (2016-2027)
    9.3 Latin America Targeted Drugs for Breast Cancer Market Size by Application
        9.3.1 Latin America Targeted Drugs for Breast Cancer Market Size by Application (2016-2021)
        9.3.2 Latin America Targeted Drugs for Breast Cancer Market Size by Application (2022-2027)
        9.3.3 Latin America Targeted Drugs for Breast Cancer Market Size by Application (2016-2027)
    9.4 Latin America Targeted Drugs for Breast Cancer Market Size by Country
        9.4.1 Latin America Targeted Drugs for Breast Cancer Market Size by Country (2016-2021)
        9.4.2 Latin America Targeted Drugs for Breast Cancer Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Targeted Drugs for Breast Cancer Market Size (2016-2027)
    10.2 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Type
        10.2.1 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Type (2016-2027)
    10.3 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Application
        10.3.1 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Application (2016-2027)
    10.4 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country
        10.4.1 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Targeted Drugs for Breast Cancer Introduction
        11.1.4 Roche Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.1.5 Roche Recent Development
    11.2 Teva
        11.2.1 Teva Company Details
        11.2.2 Teva Business Overview
        11.2.3 Teva Targeted Drugs for Breast Cancer Introduction
        11.2.4 Teva Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.2.5 Teva Recent Development
    11.3 Mylan
        11.3.1 Mylan Company Details
        11.3.2 Mylan Business Overview
        11.3.3 Mylan Targeted Drugs for Breast Cancer Introduction
        11.3.4 Mylan Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.3.5 Mylan Recent Development
    11.4 Hikma
        11.4.1 Hikma Company Details
        11.4.2 Hikma Business Overview
        11.4.3 Hikma Targeted Drugs for Breast Cancer Introduction
        11.4.4 Hikma Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.4.5 Hikma Recent Development
    11.5 Hengrui Medicine
        11.5.1 Hengrui Medicine Company Details
        11.5.2 Hengrui Medicine Business Overview
        11.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Introduction
        11.5.4 Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.5.5 Hengrui Medicine Recent Development
    11.6 Cipla
        11.6.1 Cipla Company Details
        11.6.2 Cipla Business Overview
        11.6.3 Cipla Targeted Drugs for Breast Cancer Introduction
        11.6.4 Cipla Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.6.5 Cipla Recent Development
    11.7 Reliance Group
        11.7.1 Reliance Group Company Details
        11.7.2 Reliance Group Business Overview
        11.7.3 Reliance Group Targeted Drugs for Breast Cancer Introduction
        11.7.4 Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.7.5 Reliance Group Recent Development
    11.8 Hetero
        11.8.1 Hetero Company Details
        11.8.2 Hetero Business Overview
        11.8.3 Hetero Targeted Drugs for Breast Cancer Introduction
        11.8.4 Hetero Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.8.5 Hetero Recent Development
    11.9 Pfizer
        11.9.1 Pfizer Company Details
        11.9.2 Pfizer Business Overview
        11.9.3 Pfizer Targeted Drugs for Breast Cancer Introduction
        11.9.4 Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.9.5 Pfizer Recent Development
    11.10 Eli Lilly
        11.10.1 Eli Lilly Company Details
        11.10.2 Eli Lilly Business Overview
        11.10.3 Eli Lilly Targeted Drugs for Breast Cancer Introduction
        11.10.4 Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.10.5 Eli Lilly Recent Development
    11.11 Novartis
        11.11.1 Novartis Company Details
        11.11.2 Novartis Business Overview
        11.11.3 Novartis Targeted Drugs for Breast Cancer Introduction
        11.11.4 Novartis Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.11.5 Novartis Recent Development
    11.12 CANbridge
        11.12.1 CANbridge Company Details
        11.12.2 CANbridge Business Overview
        11.12.3 CANbridge Targeted Drugs for Breast Cancer Introduction
        11.12.4 CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.12.5 CANbridge Recent Development
    11.13 Puma Biotechnology
        11.13.1 Puma Biotechnology Company Details
        11.13.2 Puma Biotechnology Business Overview
        11.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Introduction
        11.13.4 Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.13.5 Puma Biotechnology Recent Development
    11.14 AstraZeneca
        11.14.1 AstraZeneca Company Details
        11.14.2 AstraZeneca Business Overview
        11.14.3 AstraZeneca Targeted Drugs for Breast Cancer Introduction
        11.14.4 AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.14.5 AstraZeneca Recent Development
    11.15 Chugai Pharmaceutical
        11.15.1 Chugai Pharmaceutical Company Details
        11.15.2 Chugai Pharmaceutical Business Overview
        11.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Introduction
        11.15.4 Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.15.5 Chugai Pharmaceutical Recent Development
    11.16 Eisai
        11.16.1 Eisai Company Details
        11.16.2 Eisai Business Overview
        11.16.3 Eisai Targeted Drugs for Breast Cancer Introduction
        11.16.4 Eisai Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.16.5 Eisai Recent Development
    11.17 GlaxoSmithKline
        11.17.1 GlaxoSmithKline Company Details
        11.17.2 GlaxoSmithKline Business Overview
        11.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Introduction
        11.17.4 GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.17.5 GlaxoSmithKline Recent Development
    11.18 Bristol-Myers Squibb
        11.18.1 Bristol-Myers Squibb Company Details
        11.18.2 Bristol-Myers Squibb Business Overview
        11.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Introduction
        11.18.4 Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.18.5 Bristol-Myers Squibb Recent Development
    11.18 Otsuka Pharmaceutical
        .1 Otsuka Pharmaceutical Company Details
        .2 Otsuka Pharmaceutical Business Overview
        .3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Introduction
        .4 Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        .5 Otsuka Pharmaceutical Recent Development
    11.20 Merck
        11.20.1 Merck Company Details
        11.20.2 Merck Business Overview
        11.20.3 Merck Targeted Drugs for Breast Cancer Introduction
        11.20.4 Merck Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.20.5 Merck Recent Development
    11.21 BioMarin
        11.21.1 BioMarin Company Details
        11.21.2 BioMarin Business Overview
        11.21.3 BioMarin Targeted Drugs for Breast Cancer Introduction
        11.21.4 BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.21.5 BioMarin Recent Development
    11.22 Hengrui Pharmaceutical
        11.22.1 Hengrui Pharmaceutical Company Details
        11.22.2 Hengrui Pharmaceutical Business Overview
        11.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Introduction
        11.22.4 Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.22.5 Hengrui Pharmaceutical Recent Development
    11.23 Beijing Biostar Technologies
        11.23.1 Beijing Biostar Technologies Company Details
        11.23.2 Beijing Biostar Technologies Business Overview
        11.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Introduction
        11.23.4 Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.23.5 Beijing Biostar Technologies Recent Development
    11.24 Bayer
        11.24.1 Bayer Company Details
        11.24.2 Bayer Business Overview
        11.24.3 Bayer Targeted Drugs for Breast Cancer Introduction
        11.24.4 Bayer Revenue in Targeted Drugs for Breast Cancer Business (2016-2021)
        11.24.5 Bayer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of HER-2 Targeted Drugs
    Table 3. Key Players of CDK4/6 Inhibitors
    Table 4. Key Players of PARP Targeted Drugs
    Table 5. Key Players of PI3K/AKT/mTor Pathway Inhibitors
    Table 6. Key Players of ER Targeted Drugs
    Table 7. Key Players of Aromatase Inhibitors
    Table 8. Key Players of Tubulin Inhibitors
    Table 9. Key Players of VEGF Targeted Drugs
    Table 10. Key Players of YTMS Targeted Drugs
    Table 11. Key Players of Other
    Table 12. Global Targeted Drugs for Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 13. Global Targeted Drugs for Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 14. Global Targeted Drugs for Breast Cancer Market Size by Regions (2016-2021) & (US$ Million)
    Table 15. Global Targeted Drugs for Breast Cancer Market Share by Regions (2016-2021)
    Table 16. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 17. Global Targeted Drugs for Breast Cancer Market Share by Regions (2022-2027)
    Table 18. Targeted Drugs for Breast Cancer Market Trends
    Table 19. Targeted Drugs for Breast Cancer Market Drivers
    Table 20. Targeted Drugs for Breast Cancer Market Challenges
    Table 21. Targeted Drugs for Breast Cancer Market Restraints
    Table 22. Global Targeted Drugs for Breast Cancer Revenue by Players (2016-2021) & (US$ Million)
    Table 23. Global Targeted Drugs for Breast Cancer Market Share by Players (2016-2021)
    Table 24. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Breast Cancer as of 2020)
    Table 25. Ranking of Global Top Targeted Drugs for Breast Cancer Companies by Revenue (US$ Million) in 2020
    Table 26. Global 5 Largest Players Market Share by Targeted Drugs for Breast Cancer Revenue (CR5 and HHI) & (2016-2021)
    Table 27. Key Players Headquarters and Area Served
    Table 28. Key Players Targeted Drugs for Breast Cancer Product Solution and Service
    Table 29. Date of Enter into Targeted Drugs for Breast Cancer Market
    Table 30. Mergers & Acquisitions, Expansion Plans
    Table 31. Global Targeted Drugs for Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 32. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2016-2021)
    Table 33. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 34. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 35. Global Targeted Drugs for Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million)
    Table 36. Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2016-2021)
    Table 37. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 38. Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 39. North America Targeted Drugs for Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 40. North America Targeted Drugs for Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 41. North America Targeted Drugs for Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 42. North America Targeted Drugs for Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 43. North America Targeted Drugs for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. North America Targeted Drugs for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Europe Targeted Drugs for Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 46. Europe Targeted Drugs for Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Europe Targeted Drugs for Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 48. Europe Targeted Drugs for Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Europe Targeted Drugs for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) 
    Table 50. Europe Targeted Drugs for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) 
    Table 51. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 52. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 54. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2016-2021) & (US$ Million) 
    Table 56. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2022-2027) & (US$ Million) 
    Table 57. Latin America Targeted Drugs for Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 58. Latin America Targeted Drugs for Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Latin America Targeted Drugs for Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 60. Latin America Targeted Drugs for Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Latin America Targeted Drugs for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Latin America Targeted Drugs for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Type (2016-2021) (US$ Million)
    Table 64. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
    Table 65. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Application (2016-2021) (US$ Million)
    Table 66. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
    Table 67. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) 
    Table 68. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) 
    Table 69. Roche Company Details
    Table 70. Roche Business Overview
    Table 71. Roche Targeted Drugs for Breast Cancer Product
    Table 72. Roche Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 73. Roche Recent Development
    Table 74. Teva Company Details
    Table 75. Teva Business Overview
    Table 76. Teva Targeted Drugs for Breast Cancer Product
    Table 77. Teva Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 78. Teva Recent Development
    Table 79. Mylan Company Details
    Table 80. Mylan Business Overview
    Table 81. Mylan Targeted Drugs for Breast Cancer Product
    Table 82. Mylan Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 83. Mylan Recent Development
    Table 84. Hikma Company Details
    Table 85. Hikma Business Overview
    Table 86. Hikma Targeted Drugs for Breast Cancer Product
    Table 87. Hikma Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 88. Hikma Recent Development
    Table 89. Hengrui Medicine Company Details
    Table 90. Hengrui Medicine Business Overview
    Table 91. Hengrui Medicine Targeted Drugs for Breast Cancer Product
    Table 92. Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 93. Hengrui Medicine Recent Development
    Table 94. Cipla Company Details
    Table 95. Cipla Business Overview
    Table 96. Cipla Targeted Drugs for Breast Cancer Product
    Table 97. Cipla Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 98. Cipla Recent Development
    Table 99. Reliance Group Company Details
    Table 100. Reliance Group Business Overview
    Table 101. Reliance Group Targeted Drugs for Breast Cancer Product
    Table 102. Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 103. Reliance Group Recent Development
    Table 104. Hetero Company Details
    Table 105. Hetero Business Overview
    Table 106. Hetero Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 107. Hetero Recent Development
    Table 108. Pfizer Company Details
    Table 109. Pfizer Business Overview
    Table 110. Pfizer Targeted Drugs for Breast Cancer Product
    Table 111. Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 112. Pfizer Recent Development
    Table 113. Eli Lilly Company Details
    Table 114. Eli Lilly Business Overview
    Table 115. Eli Lilly Targeted Drugs for Breast Cancer Product
    Table 116. Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 117. Eli Lilly Recent Development
    Table 118. Novartis Company Details
    Table 119. Novartis Business Overview
    Table 120. Novartis Targeted Drugs for Breast Cancer Product
    Table 121. Novartis Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 122. Novartis Recent Development
    Table 123. CANbridge Company Details
    Table 124. CANbridge Business Overview
    Table 125. CANbridge Targeted Drugs for Breast Cancer Product
    Table 126. CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 127. CANbridge Recent Development
    Table 128. Puma Biotechnology Company Details
    Table 129. Puma Biotechnology Business Overview
    Table 130. Puma Biotechnology Targeted Drugs for Breast Cancer Product
    Table 131. Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 132. Puma Biotechnology Recent Development
    Table 133. AstraZeneca Company Details
    Table 134. AstraZeneca Business Overview
    Table 135. AstraZeneca Targeted Drugs for Breast Cancer Product
    Table 136. AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 137. AstraZeneca Recent Development
    Table 138. Chugai Pharmaceutical Company Details
    Table 139. Chugai Pharmaceutical Business Overview
    Table 140. Chugai Pharmaceutical Targeted Drugs for Breast Cancer Product
    Table 141. Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 142. Chugai Pharmaceutical Recent Development
    Table 143. Eisai Company Details
    Table 144. Eisai Business Overview
    Table 145. Eisai Targeted Drugs for Breast Cancer Product
    Table 146. Eisai Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 147. Eisai Recent Development
    Table 148. GlaxoSmithKline Company Details
    Table 149. GlaxoSmithKline Business Overview
    Table 150. GlaxoSmithKline Targeted Drugs for Breast Cancer Product
    Table 151. GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 152. GlaxoSmithKline Recent Development
    Table 153. Bristol-Myers Squibb Company Details
    Table 154. Bristol-Myers Squibb Business Overview
    Table 155. Bristol-Myers Squibb Targeted Drugs for Breast Cancer Product
    Table 156. Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 157. Bristol-Myers Squibb Recent Development
    Table 158. Otsuka Pharmaceutical Company Details
    Table 159. Otsuka Pharmaceutical Business Overview
    Table 160. Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Product
    Table 161. Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 162. Otsuka Pharmaceutical Recent Development
    Table 163. Merck Company Details
    Table 164. Merck Business Overview
    Table 165. Merck Targeted Drugs for Breast Cancer Product
    Table 166. Merck Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 167. Merck Recent Development
    Table 168. BioMarin Company Details
    Table 169. BioMarin Business Overview
    Table 170. BioMarin Targeted Drugs for Breast Cancer Product
    Table 171. BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 172. BioMarin Recent Development
    Table 173. Hengrui Pharmaceutical Company Details
    Table 174. Hengrui Pharmaceutical Business Overview
    Table 175. Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Product
    Table 176. Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 177. Hengrui Pharmaceutical Recent Development
    Table 178. Beijing Biostar Technologies Company Details
    Table 179. Beijing Biostar Technologies Business Overview
    Table 180. Beijing Biostar Technologies Targeted Drugs for Breast Cancer Product
    Table 181. Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 182. Beijing Biostar Technologies Recent Development
    Table 183. Bayer Company Details
    Table 184. Bayer Business Overview
    Table 185. Bayer Targeted Drugs for Breast CancerProduct
    Table 186. Bayer Revenue in Targeted Drugs for Breast Cancer Business (2016-2021) & (US$ Million)
    Table 187. Bayer Recent Development
    Table 188. Research Programs/Design for This Report
    Table 189. Key Data Information from Secondary Sources
    Table 190. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Targeted Drugs for Breast Cancer Market Share by Type: 2020 VS 2027
    Figure 2. HER-2 Targeted Drugs Features
    Figure 3. CDK4/6 Inhibitors Features
    Figure 4. PARP Targeted Drugs Features
    Figure 5. PI3K/AKT/mTor Pathway Inhibitors Features
    Figure 6. ER Targeted Drugs Features
    Figure 7. Aromatase Inhibitors Features
    Figure 8. Tubulin Inhibitors Features
    Figure 9. VEGF Targeted Drugs Features
    Figure 10. YTMS Targeted Drugs Features
    Figure 11. Other Features
    Figure 12. Global Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2027
    Figure 13. Hospital Case Studies
    Figure 14. Clinic Case Studies
    Figure 15. Drug Center Case Studies
    Figure 16. Other Case Studies
    Figure 17. Targeted Drugs for Breast Cancer Report Years Considered
    Figure 18. Global Targeted Drugs for Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 19. Global Targeted Drugs for Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 20. Global Targeted Drugs for Breast Cancer Market Share by Regions: 2020 VS 2027
    Figure 21. Global Targeted Drugs for Breast Cancer Market Share by Regions (2022-2027)
    Figure 22. Global Targeted Drugs for Breast Cancer Market Share by Players in 2020
    Figure 23. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Breast Cancer as of 2020
    Figure 24. The Top 10 and 5 Players Market Share by Targeted Drugs for Breast Cancer Revenue in 2020
    Figure 25. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2016-2021)
    Figure 26. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2022-2027)
    Figure 27. North America Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. North America Targeted Drugs for Breast Cancer Market Share by Type (2016-2027)
    Figure 29. North America Targeted Drugs for Breast Cancer Market Share by Application (2016-2027)
    Figure 30. North America Targeted Drugs for Breast Cancer Market Share by Country (2016-2027)
    Figure 31. United States Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Canada Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Europe Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Europe Targeted Drugs for Breast Cancer Market Share by Type (2016-2027)
    Figure 35. Europe Targeted Drugs for Breast Cancer Market Share by Application (2016-2027)
    Figure 36. Europe Targeted Drugs for Breast Cancer Market Share by Country (2016-2027)
    Figure 37. Germany Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. France Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. U.K. Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Italy Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Russia Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Nordic Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Asia-Pacific Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Asia-Pacific Targeted Drugs for Breast Cancer Market Share by Type (2016-2027)
    Figure 45. Asia-Pacific Targeted Drugs for Breast Cancer Market Share by Application (2016-2027)
    Figure 46. Asia-Pacific Targeted Drugs for Breast Cancer Market Share by Region (2016-2027)
    Figure 47. China Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Japan Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. South Korea Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Southeast Asia Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. India Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Australia Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Latin America Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Latin America Targeted Drugs for Breast Cancer Market Share by Type (2016-2027)
    Figure 55. Latin America Targeted Drugs for Breast Cancer Market Share by Application (2016-2027)
    Figure 56. Latin America Targeted Drugs for Breast Cancer Market Share by Country (2016-2027)
    Figure 57. Mexico Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Brazil Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. Middle East & Africa Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Middle East & Africa Targeted Drugs for Breast Cancer Market Share by Type (2016-2027)
    Figure 61. Middle East & Africa Targeted Drugs for Breast Cancer Market Share by Application (2016-2027)
    Figure 62. Middle East & Africa Targeted Drugs for Breast Cancer Market Share by Country (2016-2027)
    Figure 63. Turkey Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 64. Saudi Arabia Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 65. UAE Targeted Drugs for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 66. Roche Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 67. Teva Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 68. Mylan Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 69. Hikma Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 70. Hengrui Medicine Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 71. Cipla Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 72. Reliance Group Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 73. Hetero Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 74. Pfizer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 75. Eli Lilly Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 76. Novartis Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 77. CANbridge Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 78. Puma Biotechnology Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 79. AstraZeneca Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 80. Chugai Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 81. Eisai Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 82. GlaxoSmithKline Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 83. Bristol-Myers Squibb Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 84. Otsuka Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 85. Merck Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 86. BioMarin Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 87. Hengrui Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 88. Beijing Biostar Technologies Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 89. Bayer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2016-2021)
    Figure 90. Bottom-up and Top-down Approaches for This Report
    Figure 91. Data Triangulation
    Figure 92. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Pfizer
Eli Lilly
Novartis
CANbridge
Puma Biotechnology
AstraZeneca
Chugai Pharmaceutical
Eisai
GlaxoSmithKline
Bristol-Myers Squibb
Otsuka Pharmaceutical
Merck
BioMarin
Hengrui Pharmaceutical
Beijing Biostar Technologies
Bayer
Frequently Asked Questions
Targeted Drugs for Breast Cancer report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Targeted Drugs for Breast Cancer report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Targeted Drugs for Breast Cancer report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports